Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.read more
Fonte: esciencenews.com
Indique esta NotÃcia
Compartilhar
